Suppr超能文献

C-C趋化因子受体4缺乏会加剧小鼠早期动脉粥样硬化。

C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice.

作者信息

Tanaka Toru, Sasaki Naoto, Krisnanda Aga, Amin Hilman Zulkifli, Ito Ken, Horibe Sayo, Matsuo Kazuhiko, Hirata Ken-Ichi, Nakayama Takashi, Rikitake Yoshiyuki

机构信息

Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

Elife. 2025 Jul 3;13:RP101830. doi: 10.7554/eLife.101830.

Abstract

Chronic inflammation via dysregulation of T cell immune responses is critically involved in the pathogenesis of atherosclerotic cardiovascular disease. Improving the balance between proinflammatory T cells and anti-inflammatory regulatory T cells (Tregs) may be an attractive approach for treating atherosclerosis. Although C-C chemokine receptor 4 (CCR4) has been shown to mediate the recruitment of T cells to inflamed tissues, its role in atherosclerosis is unclear. Here, we show that genetic deletion of CCR4 in hypercholesterolemic mice accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype. This was associated with the augmentation of proinflammatory T helper type 1 (Th1) cell responses in peripheral lymphoid tissues, para-aortic lymph nodes, and atherosclerotic aorta. Mechanistically, CCR4 deficiency in Tregs impaired their suppressive function and tended to inhibit their migration to the atherosclerotic aorta, and subsequently augmented Th1 cell-mediated immune responses through defective regulation of dendritic cell function, which accelerated aortic inflammation and atherosclerotic lesion development. Thus, we revealed a previously unrecognized role for CCR4 in controlling the early stage of atherosclerosis via Treg-dependent regulation of proinflammatory T cell responses. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.

摘要

通过T细胞免疫反应失调引起的慢性炎症在动脉粥样硬化性心血管疾病的发病机制中起关键作用。改善促炎T细胞和抗炎调节性T细胞(Tregs)之间的平衡可能是治疗动脉粥样硬化的一种有吸引力的方法。尽管C-C趋化因子受体4(CCR4)已被证明可介导T细胞向炎症组织的募集,但其在动脉粥样硬化中的作用尚不清楚。在此,我们表明,高胆固醇血症小鼠中CCR4的基因缺失加速了以炎症斑块表型为特征的早期动脉粥样硬化病变的发展。这与外周淋巴组织、主动脉旁淋巴结和动脉粥样硬化主动脉中促炎1型辅助性T细胞(Th1)反应的增强有关。从机制上讲,Tregs中CCR4的缺乏损害了它们的抑制功能,并倾向于抑制它们向动脉粥样硬化主动脉的迁移,随后通过树突状细胞功能的缺陷调节增强了Th1细胞介导的免疫反应,从而加速了主动脉炎症和动脉粥样硬化病变的发展。因此,我们揭示了CCR4在通过Treg依赖性调节促炎T细胞反应来控制动脉粥样硬化早期阶段方面以前未被认识的作用。我们的数据表明CCR4是动脉粥样硬化的重要负调节因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f92d/12226018/0bb7b85f2866/elife-101830-fig1.jpg

相似文献

1
C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice.
Elife. 2025 Jul 3;13:RP101830. doi: 10.7554/eLife.101830.
2
Role of shear stress-induced red blood cell released ATP in atherosclerosis.
Am J Physiol Heart Circ Physiol. 2025 Apr 1;328(4):H774-H791. doi: 10.1152/ajpheart.00875.2024. Epub 2025 Feb 21.
3
Impaired CAMK4 Activity Limits Atherosclerosis and Reprograms Myelopoiesis.
Arterioscler Thromb Vasc Biol. 2025 Jul;45(7):e286-e306. doi: 10.1161/ATVBAHA.125.322530. Epub 2025 May 8.
5
Smooth muscle cell-specific deletion of unexpectedly leads to impaired development of advanced atherosclerotic lesions.
Am J Physiol Heart Circ Physiol. 2017 May 1;312(5):H943-H958. doi: 10.1152/ajpheart.00029.2017. Epub 2017 Mar 10.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

1
Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis.
Nat Cardiovasc Res. 2024 Feb 1;3:221-242. doi: 10.1038/s44161-023-00413-9. Epub 2024 Jan 22.
2
Novel UV-B Phototherapy With a Light-Emitting Diode Device Prevents Atherosclerosis by Augmenting Regulatory T-Cell Responses in Mice.
J Am Heart Assoc. 2024 Jan 16;13(2):e031639. doi: 10.1161/JAHA.123.031639. Epub 2024 Jan 12.
3
Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
Eur Heart J. 2023 Dec 14;44(47):4935-4949. doi: 10.1093/eurheartj/ehad666.
4
Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond.
Eur Heart J. 2023 Aug 1;44(29):2672-2681. doi: 10.1093/eurheartj/ehad304.
5
Depletion of Foxp3 regulatory T cells augments CD4 T cell immune responses in atherosclerosis-prone hypercholesterolemic mice.
Heliyon. 2022 Jul 19;8(7):e09981. doi: 10.1016/j.heliyon.2022.e09981. eCollection 2022 Jul.
6
CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells.
Circulation. 2022 Mar 8;145(10):765-782. doi: 10.1161/CIRCULATIONAHA.121.055888. Epub 2022 Feb 3.
8
CCR4 as a Therapeutic Target for Cancer Immunotherapy.
Cancers (Basel). 2021 Nov 4;13(21):5542. doi: 10.3390/cancers13215542.
9
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity.
Nat Rev Immunol. 2022 Apr;22(4):251-265. doi: 10.1038/s41577-021-00584-1. Epub 2021 Aug 13.
10
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.
Circulation. 2020 Dec 15;142(24):2299-2311. doi: 10.1161/CIRCULATIONAHA.120.049981. Epub 2020 Oct 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验